icon-folder.gif   Conference Reports for NaTaP  
  EASL - The International Liver Congress 2015
50th annual Meeting of the European
association for the Study of the Liver
Vienna, austria  april 22-26
Back grey_arrow_rt.gif
Safety and efficacy of Sofosbuvir-containing regimens in the French cohort- ANRS CO22 HEPATHER
  "613 patients started SOF-containing regimen. Compared with 3604 patients who did not start treatment, treated patients were older (58 vs. 57 years), more frequently male (65 vs. 53%), with higher BMI (26 vs.25 kg/m2), with more advanced disease (cirrhosis 74% vs. 19%; decompensated cirrhosis 6% vs. 3%) and were more frequently treatment-experienced (previous PEG/RBV+/-1st generation protease inhibitor 73% vs. 30%). Regimens distribution according to HCV genotype is described in the table 1.
Baseline characteristics did not differ according to the regimen but decompensated cirrhosis was more frequent in patients starting SOF/DCV+/-RBV regimen than in others (11% vs. 2%). The overall SVR4 rate was high from 67 to 100%. The 12 week combination SOF/DCV and SOF/SMV achieved a 81% and 95% SVR12. The addition of Ribavirin increases the SVR to 100% for both combination and an additive effect of the extending treatment duration after 12 weeks."
Reported by Jules Levin
EASL 2015 April 22-26 Vienna Austria
Victor DE LEDINGHEN1, Helene FONTAINE2, Celine DORIVAL3, Marc BOURLIERE4, Dominique LARREY5, Patrick MARCELLIN6, Sandy LUCIER3, Ventzislava PETROVSANCHEZ7, Alpha DIALLO8, Jacqueline CAPEAU9, Patrizia CARRIERI10, Christine LARSEN11, Jean-Michel PAWLOSTKY12, Jean-Claude TRINCHET13, Fabien ZOULIM14, Patrice CACOUB15, Jean DUBUISSON16, Philippe MATHURIN17, Francesco NEGRO18, Georges-Philippe PAGEAUX5, Yazdan YAZDANPANAH19, Linda WITTKOP20, Jean-Pierre ZARSKI21, Fabrice CARRAT3,22, Stanislas POL2 and the ANRS/AFEF HEPATHER Study group.